Dose-Finding with Delayed Binary Outcomes in Cancer Trials

Statistical Methods for Dose-Finding Experiments

Volumn , Issue , 2006, Pages 225-242

  Cheung, Ying Kuen ^a  

^a Department of Medicine   (United States)

Author keywords

Chronic toxicity formulation; Correct weight function; Dose finding methods in delayed toxicity outcomes; Dose finding with delayed binary outcomes; IMRT scenarios; Intensity modulated radiation therapy (IMRT); Simulation; Time to event approach and likelihood based dose finding methods; TITE CRM

Indexed keywords

TOXICITY;

CHRONIC TOXICITY; DOSE FINDING; IMRT SCENARIOS; INTENSITY-MODULATED RADIATION THERAPY; SIMULATION; TITE-CRM; WEIGHT FUNCTIONS;

RADIOTHERAPY;

EID: 84957974628     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470861258.ch11     Document Type: Chapter

References (20)

1. B. Storer and D. DeMets (1987) Current phase I/II designs: are they adequate? J. Clin. Res. Drug Development, 1, 121-30.
2. B.E. Storer (1989) Design and analysis of phase I clinical trial. Biometrics, 45(3), 925-37.
3. J. O'Quigley, M. Pepe and L. Fisher (1990) Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics, 46(1), 33-48.
4. J. Babb, A. Rogatko and S. Zacks (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine, 17(10), 1103-20.
5. Y.K. Cheung (2000) Dose escalation strategies for phase I clinical trials with late-onset toxicities. PhD Dissertation, University of Wisconsin, Madison, Wisconsin.
6. Y.K. Cheung and R. Chappell (2000) Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics, 56(4), 1177-82.
7. E.L. Korn, D. Midthune, T.T. Chen, L.V. Rubinstein, M.C. Christian and R.M. Simon (1994) A comparison of two phase I trial designs. Statistics in Medicine, 13(18), 1799-806.
8. S.N. Goodman, M.L. Zahurak and S. Piantadosi (1995) Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine, 14(11), 1149-61.
9. P.F. Thall, J.J. Lee, C.H. Tseng and E.H. Estey (1999) Accrual strategies for phase I trials with delayed patient outcome. Statistics in Medicine, 18(10), 1155-69.
10. J. Hüsing, W. Sauerwein, K. Hideghety and K.H. Jöckel (2001) A scheme for a doseescalation study when the event is lagged. Statistics in Medicine, 20(22), 3323-34.
11. Y.K. Cheung and P.F. Thall (2002) Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics, 58(1), 89-97.
12. S. Piantadosi, J.D. Fisher and S. Grossman (1998) Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemotherapy and Pharmacology, 41(6), 429-36.
13. M. Ayer, H.D. Brunk, G.M. Ewing, W.T. Reid and E. Silverman (1955) An empirical distribution function for sampling with incomplete information. Ann. Math. Statistics, 26, 641-7.
14. M.R. Storey, A. Pollack, G. Zagars, L. Smith, J. Antolak and I. Rosen (2000) Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int. J. Radiation Oncology Biology Physics, 48(3), 635-42.
15. J.M. Taylor (1995) Semi-parametric estimation in failure time mixture models. Biometrics, 51(3), 899-907.
16. D.M. Dabrowska and K.A. Doksum (1988) Estimation and testing in a two-sample generalized odds-rate model. J. Am. Statistical Assoc., 83, 744-9.
17. Y.K. Cheung and R. Chappell (2002) A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics, 58(3), 671-4.
18. D. Faries (1994) Practical modifications of the continual reassessment method for phase I cancer clinical trials. J. Biopharmaceutical Statistics, 4(2), 147-64.
19. P.F. Thall and K.E. Russell (1998) A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics, 54(1), 251-64.
20. A.T.R. Legedza and J.G. Ibrahim (2000) Longitudinal design for phase I clinical trials using the continual reassessment method. Controlled Clin. Trials, 21(6), 574-88.